An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

August 29, 2024

Study Completion Date

August 29, 2024

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

BMS-986258

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

rHuPH20

Specified dose on specified days

Trial Locations (16)

2145

Local Institution - 0013, Westmead

3084

Local Institution - 0015, Melbourne

15232

Local Institution - 0005, Pittsburgh

38138

Local Institution - 0002, Germantown

45267

Local Institution - 0016, Cincinnati

49546

Local Institution - 0010, Grand Rapids

52242

University Of Iowa Hospitals And Clinics, Iowa City

80045

Local Institution - 0007, Aurora

90033

Local Institution - 0004, Los Angeles

Local Institution - 0006, Los Angeles

1040045

Local Institution - 0008, Chuo-ku

6500017

Local Institution - 0009, Kobe

48109-5912

Local Institution - 0018, Ann Arbor

03756

Local Institution - 0012, Lebanon

T6X 1E8

Local Institution - 0014, Edmonton

V5Z 4E6

Local Institution - 0019, Vancouver

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY